Immunome (NASDAQ:IMNM – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Tuesday, Zacks.com reports. The firm currently has a $6.50 price target on the stock. Zacks Investment Research‘s price objective indicates a potential upside of 22.41% from the stock’s current price. […]
Immunome (NASDAQ:IMNM – Get Rating) issued its earnings results on Monday. The company reported ($0.68) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.81) by $0.13, Fidelity Earnings reports. Shares of IMNM traded down $0.06 on Tuesday, reaching $5.87. 1,172 shares of the company’s stock were exchanged, compared to its average […]